Treatment of Multiple Myeloma with VLA4-targeted Nanoparticles Delivering Novel c-MYC Inhibitor Prodrug

Rationale Multiple myeloma MM is an incurable malignancy derived from antibody secreting B lineage plasma cells. MM is the second most common malignancy in the United States and accounts for 1 of cancer deaths. Despite recent advances, the 5-year survival rate in patients with MM is less than 40 MM responds well to chemotherapy and remissions occur in that majority of MM patients, but all patients eventually relapse and die from progressive disease within 6 years. If the residual post-remission cells of their activation to progressive disease could be disrupted with novel targeted therapies. It would have a significant impact on the care and treatment of MM patients, particularly male veterans who are at 51 increased risk of MM compared to general public.